echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Nuocheng Jianhua TYK2 JH2 allosteric inhibitor new drug research application was accepted by the State Food and Drug Administration

    Nuocheng Jianhua TYK2 JH2 allosteric inhibitor new drug research application was accepted by the State Food and Drug Administration

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 28, Nuocheng Jianhua announced that the company's self-developed TYK2 JH2 allosteric inhibitor ICP-488 New Drug Research (IND) application has been accepted by the National Medical Products Administration (NMPA)


    ICP-488 is a selective TYK2 (tyrosine kinase 2) allosteric inhibitor.


    ICP-488 is a class 1 innovative drug with global independent intellectual property rights of Nuocheng Jianhua


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.